Using question prompts to help breast cancer patients before chemotherapy
Official title: Question Prompt List as a Tool to Promote Patient-physician Concordance in the Understanding of Information on Neoadjuvant Treatment in Breast Cancer: a Randomized Controlled Trial
Run by Region Örebro County · NCT06777420 · Data updated 2026-11-12
This study is testing whether a list of questions can help breast cancer patients feel more informed and less anxious before starting chemotherapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 218 (estimated) |
| Sponsor | Region Örebro County Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Uppsala, Region Uppsala and 2 other locations) |
| Status | Recruiting |
| Started | March 1, 2025 |
| Main results expected | January 2027 |
| Study ends | February 2027 |
| Registry record updated | April 20, 2025 |
| Trial ID | NCT06777420 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with operable early-stage breast cancer who are eligible for systemic neoadjuvant therapy.
✕Probably not a fit
Patients with locally advanced breast cancer requiring mandatory neoadjuvant therapy or those with cognitive impairments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to improve communication between healthcare providers and breast cancer patients who are planning to undergo neoadjuvant chemotherapy. It utilizes a question prompt list (QPL) to facilitate better information exchange, helping patients understand their treatment options and make informed decisions. By addressing the complexities of preoperative treatment discussions, the study seeks to reduce patient anxiety and enhance shared decision-making. The effectiveness of the QPL in this context will be evaluated to determine its impact on patient understanding and satisfaction.
Why it matters
Potential benefit: If successful, this approach could empower patients with better information and reduce anxiety during the decision-making process regarding their treatment.
How similar studies have gone: Previous studies have shown that question prompt lists can enhance patient-physician communication in various medical contexts, indicating potential success for this approach in breast cancer treatment discussions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with operable breast cancer eligible for systemic neoadjuvant therapy, according to current treatment guidelines. Exclusion Criteria: * Patients with locally advanced breast cancer where neoadjuvant therapy is mandatory rather than a treatment option. * Patients with cognitive impairment that are assessed from treating physician as unable to participate. * Patients who cannot speak/read neither Swedish nor English.
Where it's running
-
Örebro University Hospital
Örebro, Sweden Recruiting -
Akademiska Uppsala University Hospital
Uppsala, Region Uppsala, Sweden Not yet recruiting -
Västerås General Hospital
Västerås, Region Västmanland, Sweden Not yet recruiting
Study contacts
- Principal investigator: Antonis Valachis, MD, PhD — Department of Oncology, Örebro University Hospital, Sweden
- Study coordinator: Antonios Valachis, MD, PhD
- Email: antonios.valachis@regionorebrolan.se
- Phone: +46 0196021792
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
A digital tool to help decide about an ICD
We’re testing a patient-friendly online aid to help people with advanced heart failure decide whether an implantable cardioverter-defibrillator (ICD) is right for them.
-
MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC
This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.
-
Regular exercise to help women with early-stage breast cancer on hormone therapy
This study tests whether a guided, 16-week exercise program improves quality of life and fitness for women with early-stage breast cancer who are starting adjuvant hormone therapy.
-
Perioperative therapy with Retlirafusp alfa, Famitinib, and HAIC-GEMOX for locally advanced intrahepatic cholangiocarcinoma
This trial tests whether a perioperative treatment combo (Retlirafusp alfa, famitinib, and HAIC-GEMOX) can help shrink or control locally advanced intrahepatic cholangiocarcinoma before surgery and support additional therapy afterward in adults.
-
Agentic LLM for Shared Decision Making in Health Care
This project tests an agentic large language model to help patients participate in health decisions, especially for those with lower health literacy.
-
Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer
This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.